<DOC>
	<DOCNO>NCT02244229</DOCNO>
	<brief_summary>Study evaluate therapeutic effect tamsulosin finasteride symptomatic BPH patient , two medication indicate BPH belong two different pharmacological class , evaluate point view patient 's perception pathological condition impact disease general health quality life</brief_summary>
	<brief_title>Study Evaluate Therapeutic Action Tamsulosin Finasteride Symptomatic Benign Prostatic Hyperplasia ( BPH ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<criteria>Male outpatient age 5080 year IPSS &gt; = 13 Visit 1 Qmax : 415 ml/sec Visit 2 Residue urinary volume &gt; 400 ml evaluate ultrasonography SPI &gt; = 7 Visit 2 Prostate Specific Antigen ( PSA ) value &lt; 3 ng/ml Visit 1 , 310 ng/ml provide prostate cancer rule basis usual diagnostic procedure perform Centre Written inform consent Patients know history diagnosis time screen visit follow condition could influence endpoint study : Urological disturbance Medical history pelvic surgery ; palpable bladder physical examination , residue urinary volume &gt; 400 ml ; know neurological bladder disorder , bladder neck stenosis , urethral stricture , bladder prostatic cancer , bladder stone , severe diverticulum bladder , symptomatic urinary tract infection last month , recurrent urinary tract infection ( 2 last year ) ; hematuria unknown origin ; disease may affect micturition ( e.g . diabetes mellitus ) Cardiovascular diseases The follow cardiovascular disease occur last 6 month : Myocardial infarction Unstable angina Clinically significant ventricular arrhythmia Heart failure ( NYHA class III/IV ) Orthostatic hypotension Cerebral stroke Neurological disease senile dementia , multiple sclerosis , Parkinson 's disease , psychiatric disturbance , severity could prevent correct performance trial Hepatic renal insufficiency ( Biochemistry value 15 % outside normal laboratory range regard clinically relevant investigator ) Clinically significant abnormality result hematologic biochemical test perform blood sample draw screen visit Patients take take Î±blockers BPH hypertension phytotherapy BPH previous 6 week Patients take take finasteride last 6 month Patients require concomitant drug could influence pharmacodynamic pharmacokinetic property tamsulosin . In particular : alphablockers mix alphabeta blocker , alpha agonist , anticholinergic Patient take part clinical study previous 3 month Patients hypersensitivity allergic reaction previously prescribe alphablocker ( ) finasteride Patients judge investigator inappropriate inclusion study</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>